Above: CELLINK and Lonza Join Forces to Offer Complete 3D Cell Culture Workflows/Image Credit: CELLINK
CELLINK, a global leader in developing and delivering life-science solutions, has joined forces with Lonza, the Swiss Chemicals and Biotechnology Company, to offer a comprehensive 3D Bioprinting solution designed to advance complete 3D cell culture workflows.
The solution integrates CELLINK’s 3D bioprinting instruments and bioinks with Lonza’s broad selection of human-derived primary cells and supporting culture media. Cell biologists can now rely on this high-performing product portfolio to successfully execute even the most demanding 3D bioprinting work and boost their scientific research.
[penci_blockquote style=”style-2″ align=”none” author=”Ginger Lohman, Biodispensing Product Manager, CELLINK” font_style=”italic” uppercase=”false” text_size=”18″]Everything we do at CELLINK, from live-cell imaging to our innovative bioprinting systems and bioinks, is meant to support our customers with the products and services needed for them to more effectively and efficiently research solutions to some of the most important challenges of our time. Challenges such as cancer therapeutics, regenerative medicine, and the testing and development of drugs, to name a few. When it came time to expand our portfolio into complete 3D cell culture workflows, we knew it was critical that we brought the right partner on board. We’re confident that Lonza is that partner.[/penci_blockquote]
Under the agreement, CELLINK will provide this complete solution through its global sales channels, supported by Lonza’s well-established logistics processes.
[penci_blockquote style=”style-2″ align=”none” author=”Katrin Hoeck, Head of Marketing for Cell Analysis and Testing Solutions, Lonza” font_style=”italic” uppercase=”false” text_size=”18″]Cell biology laboratories are constantly seeking innovative new technologies to enhance their experimental workflows and help deliver on their promise to drive the next research breakthrough. Our broad panel of human-derived primary cells is specifically engineered to enable researchers to develop biological in vitro model systems that more closely reflect disease biology. This new collaboration with CELLINK will enable our customers to build physiologically-relevant 3D models to accelerate target identification/validation, investigation of mechanisms of action, and safety testing in drug discovery.[/penci_blockquote]
Above: CELLINK complete 3D Bioprinting family/Image Credit: CELLINK
Cell biology laboratories on a global scale are increasingly adopting 3D over 2-dimensional (2D) cell culture approaches because 3D cell culturing more closely resembles the cells’ in vivo environment and offers a more accurate and reliable means of predicting and analyzing cell behavior. However, as researchers look to create increasingly complex 3D constructs, finding solutions to structural and material engineering challenges is becoming progressively more important. 3D bioprinting has emerged as a powerful technology for engineering complex 3D tissues for in vitro drug discovery research.
[penci_related_posts taxonomies=”undefined” title=”Related Posts” background=”” border=”Blue” thumbright=”yes” number=”4″ style=”grid” align=”none” displayby=”cat” orderby=”random”]
CELLINK provides a wide range of user-friendly and flexible 3D bioprinting systems that are designed to offer improved levels of sterility, precision, and versatility. Furthermore, the company’s Bioink is the world’s first universal bioink designed to print complex 3D human tissue constructs with any 3D bioprinting system. Offering superior biocompatibility, cell viability, printability, and consistency, this biomaterial can be modified with peptides and growth factors to develop a series of customized bioink formulations to meet varying application needs.
Robust, viable cells are an essential component of any successful 3D bioprinting and cell culture application. Lonza offers an extensive array of high-quality human-derived primary cells and culture media specifically developed to improve experimental reliability and validity. All cells are ethically sourced and authenticated by thorough quality control testing, while the media are optimized for each cell type to support optimal, consistent growth and maintain the tissue-specific characteristics.
About Lonza Group: Lonza Group is a Swiss multinational, chemicals, and biotechnology company, headquartered in Basel, with major facilities in Europe, North America, and South Asia. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries.
Lonza combines technological innovation with world-class manufacturing and process excellence. Together, these enable its customers to deliver their discoveries in the healthcare, preservation, and protection sectors.
About Manufactur3D Magazine: Manufactur3D is an online magazine on 3D Printing. Visit our Global News page for more updates on Global 3D Printing News. To stay up-to-date about the latest happenings in the 3D printing world, like us on Facebook or follow us on LinkedIn.
